Defining the "Tipping Point" to Success as a Surgeon-scientist: An Analysis of Applicants and Awardees of the American College of Surgeons Jacobson Promising Investigator Award.

BACKGROUND: Since 2005, the American College of Surgeons has administered the Jacobson Promising Investigator Award (JPIA), which recognizes surgeon-scientists at the "tipping point" of their research careers. OBJECTIVE: We retrospectively reviewed JPIA applicants to identify factors associated with selection for the award and future research success. METHODS: Profiles were reviewed for all applicants between 2008 and 2018, at the time of application and as of 2019. Web of Science and NIH Reporter metrics were also reviewed for each applicant. RESULTS: Eleven of 97 applicants were selected for the JPIA. At the time of application, awardees were more likely to have extramural (NIH K-award) versus intramural (KL2) or other career development award funding (55% vs 33%, P = 0.03) and more publications [median 70 (interquartile range, IQR 55-100) vs 40 (IQR 22-67), P = 0.03]. Post-application, JPIA awardees were more likely to achieve a higher h-Index and m-quotient compared to nonawardees (P < 0.001 for both). All JPIA recipients received new NIH funding post-award, including 82% with R01 funding, compared to 23% of nonselected applicants (P < 0.0001). Over $48 million from NIH was awarded to JPIA recipients since 2008, representing a 147-fold return on investment. CONCLUSIONS: Selection for the JPIA is associated with previous extramural NIH K award and, on average, 70 peer-reviewed publications at the time of application. Receipt of the JPIA is associated with a high rate of subsequent NIH R01 funding and publication metrics. The JPIA is an excellent indicator of "tipping point" success in academic surgery and demonstrates the huge potential impact of philanthropic support on early career surgeon-investigators.

The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children.

BACKGROUND AND AIMS: Disease progression in children with primary sclerosing cholangitis (PSC) is variable. Prognostic and risk-stratification tools exist for adult-onset PSC, but not for children. We aimed to create a tool that accounts for the biochemical and phenotypic features and early disease stage of pediatric PSC. APPROACH AND RESULTS: We used retrospective data from the Pediatric PSC Consortium. The training cohort contained 1,012 patients from 40 centers. We generated a multivariate risk index (Sclerosing Cholangitis Outcomes in Pediatrics [SCOPE] index) that contained total bilirubin, albumin, platelet count, gamma glutamyltransferase, and cholangiography to predict a primary outcome of liver transplantation or death (TD) and a broader secondary outcome that included portal hypertensive, biliary, and cancer complications termed hepatobiliary complications (HBCs). The model stratified patients as low, medium, or high risk based on progression to TD at rates of <1%, 3%, and 9% annually and to HBCs at rates of 2%, 6%, and 13% annually, respectively (P < 0.001). C-statistics to discriminate outcomes at 1 and 5 years were 0.95 and 0.82 for TD and 0.80 and 0.76 for HBCs, respectively. Baseline hepatic fibrosis stage was worse with increasing risk score, with extensive fibrosis in 8% of the lowest versus 100% with the highest risk index (P < 0.001). The model was validated in 240 children from 11 additional centers and performed well. CONCLUSIONS: The SCOPE index is a pediatric-specific prognostic tool for PSC. It uses routinely obtained, objective data to predict a complicated clinical course. It correlates strongly with biopsy-proven liver fibrosis. SCOPE can be used with families for shared decision making on clinical care based on a patient's individual risk, and to account for variable disease progression when designing future clinical trials.

Colorectal Dysplasia and Cancer in Pediatric-Onset Ulcerative Colitis Associated With Primary Sclerosing Cholangitis.

Inflammatory bowel disease (IBD), especially when associated with primary sclerosing cholangitis (PSC), is a risk factor for developing colorectal cancer (CRC).1-3 We aimed to determine the incidence of CRC in a large cohort of pediatric-onset PSC-ulcerative colitis (UC) patients.